|
1
|
Sheikh MA, Althouse AD, Freese KE, Soisson
S, Edwards RP, Welburn S, Sukumvanich P, Comerci J, Kelley J,
LaPorte RE and Linkov F: USA endometrial cancer projections to
2030: Should we be concerned? Future Oncol. 10:2561–2568. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kulhan M, Kulhan G, Nayki U, Nayki C, Ulug
P, Sipahi M and Yildirim Y: Assessment of clinicopathological
features, evaluation of treatment, and prognosis of clear cell and
serous papillary endometrial carcinoma. Ginekol Pol. 87:570–574.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dessai SB, Adrash D, Geetha M, Arvind S,
Bipin J, Nayanar S, Sachin K, Biji MS and Balasubramanian S:
Pattern of care in operable endometrial cancer treated at a
rural-based tertiary care cancer center. Indian J Cancer.
53:416–419. 2016.PubMed/NCBI
|
|
5
|
Ouldamer L, Bendifallah S, Body G, Touboul
C, Graesslin O, Raimond E, Collinet P, Coutant C, Bricou A, Lavoué
V, et al: Incidence, patterns and prognosis of first distant
recurrence after surgically treated early stage endometrial cancer:
Results from the multicentre FRANCOGYN study group. Eur J Surg
Oncol. 45:672–678. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Francis SR, Ager BJ, Do OA, Huang YJ,
Soisson AP, Dodson MK, Werner TL, Sause WT, Grant JD and Gaffney
DK: Recurrent early stage endometrial cancer: Patterns of
recurrence and results of salvage therapy. Gynecol Oncol.
154:38–44. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bogani G, Dowdy SC, Cliby WA, Ghezzi F,
Rossetti D, Frigerio L and Mariani A: Management of endometrial
cancer: Issues and controversies. Eur J Gynaecol Oncol. 37:6–12.
2016.PubMed/NCBI
|
|
8
|
Evans T, Sany O, Pearmain P, Ganesan R,
Blann A and Sundar S: Differential trends in the rising incidence
of endometrial cancer by type: data from a UK population-based
registry from 1994 to 2006. Br J Cancer. 104:1505–1510. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rajasekhar VK and Begemann M: Concise
review: Roles of polycomb group proteins in development and
disease: A stem cell perspective. Stem Cells. 25:2498–2510. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jiang L, Li J and Song L: Bmi-1, stem
cells and cancer. Acta Biochim Biophys Sin (Shanghai). 41:527–534.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Beà S, Tort F, Pinyol M, Puig X, Hernández
L, Hernández S, Fernandez PL, van Lohuizen M, Colomer D and Campo
E: BMI-1 gene amplification and overexpression in hematological
malignancies occur mainly in mantle cell lymphomas. Cancer Res.
61:2409–2412. 2001.PubMed/NCBI
|
|
12
|
Kim JH, Yoon SY, Jeong SH, Kim SY, Moon
SK, Joo JH, Lee Y, Choe IS and Kim JW: Overexpression of Bmi-1
oncoprotein correlates with axillary lymph node metastases in
invasive ductal breast cancer. Breast. 13:383–388. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang H, Pan K, Zhang HK, Weng DS, Zhou J,
Li JJ, Huang W, Song HF, Chen MS and Xia JC: Increased
polycomb-group oncogene Bmi-1 expression correlates with poor
prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol.
134:535–541. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang X, Wang CX, Zhu CB, Zhang J, Kan SF,
Du LT, Li W, Wang LL and Wang S: Overexpression of Bmi-1 in uterine
cervical cancer: Correlation with clinicopathology and prognosis.
Int J Gynecol Cancer. 20:1597–1603. 2010.PubMed/NCBI
|
|
15
|
Honig A, Weidler C, Häusler S,
Krockenberger M, Buchholz S, Köster F, Segerer SE, Dietl J and
Engel JB: Overexpression of polycomb protein BMI-1 in human
specimens of breast, ovarian, endometrial and cervical cancer.
Anticancer Res. 30:1559–1564. 2010.PubMed/NCBI
|
|
16
|
Guo BH, Feng Y, Zhang R, Xu LH, Li MZ,
Kung HF, Song LB and Zeng MS: Bmi-1 promotes invasion and
metastasis, and its elevated expression is correlated with an
advanced stage of breast cancer. Mol Cancer. 10:102011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yuan W, Yuan Y, Zhang T and Wu S: Role of
Bmi-1 in regulation of ionizing irradiation-induced
epithelial-mesenchymal transition and migration of breast cancer
cells. PLoS One. 10:e01187992015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang MC, Jiao M, Wu T, Jing L, Cui J, Guo
H, Tian T, Ruan ZP, Wei YC, Jiang LL, et al: Polycomb complex
protein BMI-1 promotes invasion and metastasis of pancreatic cancer
stem cells by activating PI3K/AKT signaling, an ex vivo, in vitro,
and in vivo study. Oncotarget. 7:9586–9599. 2016.PubMed/NCBI
|
|
19
|
Silva J, García V, García JM, Peña C,
Domínguez G, Díaz R, Lorenzo Y, Hurtado A, Sánchez A and Bonilla F:
Circulating Bmi-1 mRNA as a possible prognostic factor for advanced
breast cancer patients. Breast Cancer Res. 9:R552007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Abe S, Yamashita SI, Miyahara SO, Wakahara
J, Yamamoto L, Mori R, Imamura N, Yoshida Y, Waseda R, Hiratsuka M,
et al: Prognostic significance of BMI-1 But Not MEL-18 expression
in pulmonary squamous cell carcinoma. Anticancer Res. 37:1923–1929.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang X, Tian T, Sun W, Liu C and Fang X:
Bmi-1 overexpression as an efficient prognostic marker in patients
with nonsmall cell lung cancer. Medicine (Baltimore). 96:e73462017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Engelsen IB, Mannelqvist M, Stefansson IM,
Carter SL, Beroukhim R, Øyan AM, Otte AP, Kalland KH, Akslen LA and
Salvesen HB: Low BMI-1 expression is associated with an activated
BMI-1-driven signature, vascular invasion, and hormone receptor
loss in endometrial carcinoma. Br J Cancer. 98:1662–1669. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li F, Liang A, Lv Y, Liu G, Jiang A and
Liu P: MicroRNA-200c inhibits epithelial-mesenchymal transition by
targeting the BMI-1 gene through the Phospho-AKT pathway in
endometrial carcinoma cells in vitro. Med Sci Monit. 23:5139–5149.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
FIGO Committee on Gynecologic Oncology, .
FIGO staging for carcinoma of the vulva, cervix, and corpus uteri.
Int J Gynaecol Obstet. 125:97–98. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hellmann F, Verdi M, Schlemper BR Jr and
Caponi S: 50th anniversary of the Declaration of Helsinki: The
double standard was introduced. Arch Med Res. 45:600–601. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Makker A and Goel MM: Tumor progression,
metastasis, and modulators of epithelial-mesenchymal transition in
endometrioid endometrial carcinoma: An update. Endocr Relat Cancer.
23:R85–R111. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mahdi H, Jernigan A, Nutter B, Michener C
and Rose PG: Lymph node metastasis and pattern of recurrence in
clinically early stage endometrial cancer with positive
lymphovascular space invasion. J Gynecol Oncol. 26:208–213. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Devis L, Moiola CP, Masia N,
Martinez-Garcia E, Santacana M, Stirbat TV, Brochard-Wyart F,
García Á, Alameda F, Cabrera S, et al: Activated leukocyte cell
adhesion molecule (ALCAM) is a marker of recurrence and promotes
cell migration, invasion, and metastasis in early-stage
endometrioid endometrial cancer. J Pathol. 241:475–487. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Giannella L, Cerami LB, Setti T, Bergamini
E and Boselli F: Prediction of endometrial hyperplasia and cancer
among premenopausal Women with abnormal uterine bleeding. Biomed
Res Int. 2019:85981522019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Khafaga A and Goldstein SR: Abnormal
uterine bleeding. Obstet Gynecol Clin North Am. 46:595–605. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Goldstein SR and Lumsden MA: Abnormal
uterine bleeding in perimenopause. Climacteric. 20:414–420. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Munro MG, Critchley HOD and Fraser IS;
FIGO Menstrual Disorders Committee, : The two FIGO systems for
normal and abnormal uterine bleeding symptoms and classification of
causes of abnormal uterine bleeding in the reproductive years: 2018
revisions. Int J Gynaecol Obstet. 143:393–408. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stovall TG, Photopulos GJ, Poston WM, Ling
FW and Sandlers LG: Pipelle endometrial sampling in patients with
known endometrial carcinoma. Obstet Gynecol. 77:954–959.
1991.PubMed/NCBI
|
|
35
|
Guido RS, Kanbour-Shakir A, Rulin MC and
Christopherson WA: Pipelle endometrial sampling. Sensitivity in the
detection of endometrial cancer. J Reprod Med. 40:553–555.
1995.PubMed/NCBI
|
|
36
|
Peng HX, Liu XD, Luo ZY, Zhang XH, Luo XQ,
Chen X, Jiang H and Xu L: Upregulation of the proto-oncogene Bmi-1
predicts a poor prognosis in pediatric acute lymphoblastic
leukemia. BMC Cancer. 17:762017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Song W, Tao K, Li H, Jin C, Song Z, Li J,
Shi H, Li X, Dang Z and Dou K: Bmi-1 is related to proliferation,
survival and poor prognosis in pancreatic cancer. Cancer Sci.
101:1754–1760. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang Y, Zhe H, Ding Z, Gao P, Zhang N and
Li G: Cancer stem cell marker Bmi-1 expression is associated with
basal-like phenotype and poor survival in breast cancer. World J
Surg. 36:1189–1194. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lei X, Li YF, Chen GD, Ou DP, Qiu XX, Zuo
CH and Yang LY: Ack1 overexpression promotes metastasis and
indicates poor prognosis of hepatocellular carcinoma. Oncotarget.
6:40622–40641. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang M, Xie X and Ding Y: SALL4 is a
marker of poor prognosis in serous ovarian carcinoma promoting
invasion and metastasis. Oncol Rep. 35:1796–1806. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Acloque H, Adams MS, Fishwick K,
Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions:
The importance of changing cell state in development and disease. J
Clin Invest. 119:1438–1449. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zeisberg M and Neilson EG: Biomarkers for
epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kalluri R and Weinberg RA: The basics of
epithelial--mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tam WL and Weinberg RA: The epigenetics of
epithelial-mesenchymal plasticity in cancer. Nat Med. 19:1438–1449.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu
LJ, Kong QL, Xu LH, Zhang X, Liu WL, et al: The polycomb group
protein Bmi-1 represses the tumor suppressor PTEN and induces
epithelial-mesenchymal transition in human nasopharyngeal
epithelial cells. J Clin Invest. 119:3626–3636. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li H, Song F, Chen X, Li Y, Fan J and Wu
X: Bmi-1 regulates epithelial-to-mesenchymal transition to promote
migration and invasion of breast cancer cells. Int J Clin Exp
Pathol. 7:3057–3064. 2014.PubMed/NCBI
|
|
49
|
Yi C, Li BB and Zhou CX: Bmi-1 expression
predicts prognosis in salivary adenoid cystic carcinoma and
correlates with epithelial-mesenchymal transition-related factors.
Ann Diagn Pathol. 22:38–44. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu Y, Chu Z, Li Q, Peng B, Xu S, Lian CG
and Geng S: Downregulation of Bmi-1 suppresses
epithelial-mesenchymal transition in melanoma. Oncol Rep.
37:139–146. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zheng Z, Bao F, Chen X, Huang H and Zhang
X: MicroRNA-330-3p expression indicates good prognosis and
suppresses cell proliferation by targeting Bmi-1 in osteosarcoma.
Cell Physiol Biochem. 46:442–450. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Joensuu K, Hagstrom J, Leidenius M,
Haglund C, Andersson LC, Sariola H and Heikkilä P: Bmi-1, c-myc and
Snail expression in primary breast cancers and their
metastases-elevated Bmi-1 expression in late breast cancer
relapses. Virchows Arch. 459:31–39. 2011. View Article : Google Scholar : PubMed/NCBI
|
